Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX23.989,13+1,01 %

Gold3.335,600,00 %

Öl (Brent)69,62+1,94 %

Dow Jones44.396,02-0,36 %

US Tech 10022.685,81-0,17 %

EUR/USD1,17439+0,29 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Algernon Pharmaceuticals Registered (A) (Old) Aktie

Aktie

ISIN: CA01559R1038 WKN: A2PEGU Land Flagge CA

Kanada

Neueste Nachrichten

Algernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling $621,000 30.06.25 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
Algernon Announces $1M Private Placement 27.05.25 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition 23.05.25 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
Algernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer’s Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology 13.05.25 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
Algernon Announces Warrant Extension 05.05.25 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease 08.04.25 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing 06.03.25 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study 11.02.25 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity Investment 05.02.25 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
Algernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease Patent 06.01.25 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
Algernon Announces Warrant Extension 05.11.24 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
Algernon Pharmaceuticals Announces Closing of Private Placement 20.08.24 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)

1
2

Meistgelesen

30 Tage
12 Monate

Algernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling ... 124 Leser

Algernon Pharmaceuticals Announces Private Placement 588 Leser
Algernon Pharmaceuticals Announces Closing of Private Placement 276 Leser
Algernon Pharmaceuticals Announces Closing of Private Placement 180 Leser
Algernon Announces Warrant Extension 152 Leser
Algernon Pharmaceuticals Announces Increase to Private Placement 144 Leser
Algernon Pharmaceuticals Announces Increase to Private Placement 140 Leser
Algernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling ... 124 Leser
Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast ... 124 Leser
Algernon Announces Warrant Extension 124 Leser
Algernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease ... 120 Leser